Scarica l'app Stockscreener
10.69
1.14%
0.12
Dopo l'orario di chiusura:
10.02
-0.67
-6.27%
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study on agenT-797 with Checkpoint Inhibitors for PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - geneonline.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - Investing News Network
HC Wainwright Issues Positive Outlook for INKT Earnings - marketbeat.com
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - Sahm
MiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026 - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of ... - Caledonian Record
Cancer and ARDS data from MiNK's cell therapy heads to ASGCT - Stock Titan
MiNK Therapeutics’ (INKT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society 2026 International Conference - Investing News Network
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - Investing News Network
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside - tipranks.com
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2025 Earnings Conference - Moomoo
MiNK Therapeutics (NASDAQ: INKT) expands iNKT trials as losses grow and going-concern risk flagged - Stock Titan
MiNK Therapeutics 2025 10-K: Net loss $(2.93) per share, $12.49M net loss - TradingView
MiNK Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
MiNK Therapeutics Reports 2025 Results and Advances Phase 2 iNKT Cell Therapy Programs for ARDS, GVHD, and Oncology - Minichart
MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
INKT: Durable clinical results, strong cash position, and major trial milestones expected in 2026 - TradingView
Earnings call transcript: MiNK Therapeutics’ Q4 2025 shows cash boost amid wider losses - Investing.com Australia
MiNK Therapeutics Q4 Earnings Call Highlights - marketbeat.com
MiNK Therapeutics (NASDAQ: INKT) details 2025 loss and cash runway into 2026 - Stock Titan
MiNK Therapeutics Initiates Phase 2 Trials for ARDS and GVHD, Planning Multiple Clinical Catalysts for 2026 - Quiver Quantitative
Ideas Watch: What is the target price for MiNK Therapeutics Inc stockWeekly Trade Report & Reliable Trade Execution Plans - baoquankhu1.vn
Whale Trades: Whats the fair value of MiNK Therapeutics Inc stock2026 Momentum Check & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
MiNK Therapeutics pediatric cancer breakthrough sparks stock rally - MSN
Activity Recap: Is MiNK Therapeutics Inc stock heavily shorted2026 Rallies & Low Risk Growth Stock Ideas - baoquankhu1.vn
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight ... - Caledonian Record
MiNK Therapeutics clarifies status of agenT-797 combination trial discussions By Investing.com - Investing.com Australia
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations - TipRanks
Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments - TradingView
MiNK Therapeutics clarifies status of agenT-797 combination trial discussions - Investing.com
MiNK Therapeutics in talks on agenT-797 combos; no binding deals disclosed - TradingView
Potential agenT-797 trial and investment talks at MiNK (NASDAQ: INKT) - Stock Titan
Weekly Trades: Is MiNK Therapeutics Inc a defensive stock2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Responsive Playbooks and the INKT Inflection - Stock Traders Daily
Death Cross: What is MiNK Therapeutics Incs revenue forecast2026 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
MiNK Therapeutics (INKT) officer Form 3 shows 40 common shares held - Stock Titan
Why is MiNK Therapeutics stock trading lower on Wednesday? - MSN
If You Invested $1,000 in Mink Therapeutics, Inc. (INKT) - Stock Titan
MiNK Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 6Q40 | US6036932019 - marketscreener.com
MiNK Therapeutics appoints new principal financial and accounting officers By Investing.com - Investing.com Australia
MiNK Therapeutics Appoints New Principal Financial Officer – SEC 8-K Filing Details and Company Information - Minichart
MiNK Therapeutics appoints new principal financial and accounting officers - Investing.com
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers - TipRanks
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):